Fate of circulating amino-terminal propeptide of type III procollagen in conscious pigs

1993 ◽  
Vol 265 (1) ◽  
pp. R139-R145
Author(s):  
L. T. Jensen ◽  
J. H. Henriksen ◽  
J. Risteli ◽  
H. P. Olesen ◽  
M. D. Nielsen ◽  
...  

The amino-terminal propeptide of type III procollagen (PIIINP, M(r) 42,000) is a promising marker for the formation of type III collagen of granulation tissue in experimental and clinical studies. The disposal kinetics of circulating PIIINP is, however, almost unknown. In conscious pigs with a thoracic duct-venous shunt, 125I-labeled PIIINP was injected intravenously. The initial distribution volume was 2.2 liters, which was 1.7 times the plasma volume (P < 0.01). The disappearance curve was three-phased, with an initial steep decline (t1/2 58 min), followed by two slower phases (t1/2 239 min and 289 h). Consecutive gel filtrations showed that the initial slope of the plasma disappearance curve corresponded to the plasma clearance of the intact PIIINP. The initial plasma clearance was 26.5 ml plasma/min, whereas the urinary clearance was 8.7 ml plasma/min (P < 0.01). The other components of the plasma disappearance curve originated from the formation and disappearance of a high and a low molecular weight (MW) fraction as part of the degradation of PIIINP. The high MW fraction (approximately M(r) 90,000) was similar to a previously described, but not further characterized, PIIINP immunoreactive component. The existence of the low MW fraction (approximately M(r) 20,000) has not been reported before. The lymphatic recirculation of intact PIIINP was rapid, and the lymph-serum ratio was almost constant within 1 h of injection. We conclude that the t1/2 of circulating PIIINP is 58 min, that PIIINP escapes the circulation very quickly, and that the degradation of PIIINP includes at least two intermediary steps.

1989 ◽  
Vol 9 (2) ◽  
pp. 177-183 ◽  
Author(s):  
Kirsten D. Bentsen ◽  
Jens H. Henriksen ◽  
Steen Boesby ◽  
Kim Hørslev-Petersen ◽  
Ib Lorenzen

1984 ◽  
Vol 30 (3) ◽  
pp. 488-490 ◽  
Author(s):  
A M Gressner ◽  
H H Neu

2015 ◽  
Vol 7 (9) ◽  
pp. 745-755 ◽  
Author(s):  
Richard I. G. Holt ◽  
Walailuck Böhning ◽  
Nishan Guha ◽  
Christiaan Bartlett ◽  
David A. Cowan ◽  
...  

Burns ◽  
2002 ◽  
Vol 28 (8) ◽  
pp. 766-771 ◽  
Author(s):  
Dietmar Ulrich ◽  
Ernst-Magnus Noah ◽  
Elmar Reinhardt Burchardt ◽  
Derek Atkins ◽  
Norbert Pallua

1991 ◽  
Vol 124 (3) ◽  
pp. 278-282 ◽  
Author(s):  
Lars T. Jensen ◽  
Jens O.L. Jørgensen ◽  
Juha Risteli ◽  
Jens S. Christiansen ◽  
Ib Lorenzen

Abstract. The effect of increasing doses of growth hormone on collagen synthesis in GH-treated GH-deficient patients was determined in a short-term study. The synthesis of type I and III collagen was estimated by measurements of the carboxyterminal propeptide of type I procollagen and the aminoterminal propeptide of type III procollagen. Type I collagen is mainly found in bone and type III collagen in loose connective tissue. We observed a GH dose dependency of both procollagen propeptides. Serum type I procollagen propeptide was significantly higher following GH doses of 4 and 6 IU/day for 14 days compared with 2 IU/day (normal replacement dose) (p=0.04). Withdrawal of GH therapy for 14 days resulted in wider variation, but not significantly different from the levels at 2, 4 and 6 IU/day. A dose dependency was found regarding type III procollagen propeptide, showing significantly higher serum concentrations at a GH dose of 4 IU/day compared with 2 IU/day (p=0.001), and of 6 IU/day compared with 4 IU/day (p=0.001). Withdrawal of GH therapy resulted in significantly lower type III procollagen propeptide concentrations compared with those at a GH dose of 4 and 6 IU/day (p=0.03). Serum type III procollagen propeptide increased twice as much as type I procollagen propeptide, by 47 vs 25%, at a GH dose of 6 IU/day compared with 2 IU/day. The differences between the effects on type I and type III collagen may reflect differences in secretion or turn-over rate of collagen in bone and loose connective tissue. Serum type I and type III procollagen propeptides may prove useful as monitors of GH therapy, especially regarding the GH dose levels in the individual patients.


Author(s):  
Cindy Soendersoe Knudsen ◽  
Lene Heickendorff ◽  
Ebba Nexo

AbstractRecently, measurement of amino terminal propeptide of type III procollagen (PIIINP) was introduced as a part of the hepatic cirrhotic marker enhanced liver fibrosis™ test on the automated ADVIA CentaurWe analyzed four control samples 20 times over a period of 5 days. Centaur PIIINP assay measurements were compared with the widely used UniQ PIIINP RIA assay (Orion Diagnostica, Espoo, Finland) using 55 patient samples (range=3.7–43.3 µg/L). Furthermore, we established a reference interval based on samples from 287 blood donors.In the concentration range 2.5–11.9 µg/L, the total imprecision was below 8%. Comparison with the UniQ PIIINP RIA assay yielded: Centaur PIIINP µg/L=1.9×(UniQ PIIINP RIA)+0.6 µg/L, rWe conclude that the Centaur PIIINP assay is suitable for routine use with our newly defined reference interval. The results obtained by Centaur correlates well with those obtained by the previously employed RIA, though the absolute values are higher.


1976 ◽  
Vol 70 (1) ◽  
pp. 205-216 ◽  
Author(s):  
Hans NOWACK ◽  
Bjorn R. OLSEN ◽  
Rupert TIMPL

Sign in / Sign up

Export Citation Format

Share Document